Addressing Loss of Exclusivity in Pharma

Bristol Myers Squibb’s latest third-quarter report highlighted an impressive 8% revenue growth, driven primarily by their diversified drug portfolio and strategic market positioning. This resilience underscores the evolving challenges in the pharmaceutical landscape, especially as major players confront the inevitable impact of loss of exclusivity (LoE) on key products. With blockbuster drugs eventually losing their exclusive patent protection, pharmaceutical companies face significant revenue erosion when generic and biosimilar competition enters the market.

The Challenge of LoE in the Pharma Sector

For an industry built on high stakes and extensive R&D investments, the end of a drug’s exclusivity can translate into billions in lost revenue. The task of offsetting these losses while maintaining sustainable growth and innovation is complex, requiring robust strategies and new approaches to commercialisation. This is where AI and advanced technology step in, providing the insights and capabilities necessary to navigate the post-LoE period with agility and foresight.